Advertisement

Archives of Dermatological Research

, Volume 311, Issue 1, pp 19–27 | Cite as

Mortality and risk factors among Israeli bullous pemphigoid patients

  • Mati Rozenblat
  • Awad Halaj
  • Tal Rozenblat
  • Shani Fisher
  • Mohammad Sah
  • Roni P. Dodiuk-Gad
  • Michael Ziv
Original Paper
  • 63 Downloads

Abstract

There are differences concerning reported mortality rates and prognostic factors of bullous pemphigoid (BP) patients in different studies. Our objectives were to evaluate the mortality rates and prognostic factors among Israeli BP patients compared to matched control subjects. Three age- and sex-matched patients without BP (n = 261) who were treated in our clinic were selected and compared to BP patients (n = 87). Mean survival period of the BP group was 4.1 years (95% CI: 3.3–4.8 years) and 5.9 years among the non-BP group (95% CI: 5.6–6.3 years). The 1-year mortality rate was 24.1% for the BP group and 6.5% for the control group. In multivariate analysis, age above 80 was a significant risk factor for mortality [HR 3.22 (95% CI, 1.15–8.96), p = 0.03], while statins intake had a protective role [HR 0.36 (95% CI, 0.15–0.88), p = 0.03]. In univariant analysis, dementia [HR 2.44 (95% CI, 1.02–5.99), p = 0.04] was a risk factor. In conclusion, BP patients’ mortality is correlated to increasing age at diagnosis, dementia, and statins use. Statins’ protective role is newly discussed in the literature.

Keywords

Bullous pemphigoid Pemphigoid Mortality Prognosis 

Notes

Funding

No funding was received for this research.

Compliance with ethical standards

Conflict of interest

The author(s) declare that they have no conflict of interests.

Research involving human participants and/or animals

Reviewed and approved by Emek Medical Center IRB (institutional review board), approval number: 151-15.

References

  1. 1.
    Bastuji-Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E, Roujeau JC, Bernard P, Guillaume JC, Ingen-Housz-Oro S, Maillard H (2011) Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 131(3):637–643Google Scholar
  2. 2.
    Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, Lorette G, Bonnetblanc JM, Prost C (1995) Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous diseases French study group. Arch Dermatol 131(1):48–52Google Scholar
  3. 3.
    Brick KE, Weaver CH, Savica R, Lohse CM, Pittelkow MR, Boeve BF, Gibson LE, Camilleri MJ, Wieland CN (2014) A population-based study of the association between bullous pemphigoid and neurologic disorders. J Am Acad Dermatol 71(6):1191–1197Google Scholar
  4. 4.
    Brick KE, Weaver CH, Lohse CM, Pittelkow MR, Lehman JS, Camilleri MJ, Al-Hashimi M, Wieland CN (2014) Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol 71(1):92–99Google Scholar
  5. 5.
    Brown A, Dalpé G, Mathieu M, Kothary R (1995) Cloning and characterization of the neural isoforms of human dystonin. Genomics 29(3):777–780Google Scholar
  6. 6.
    Bystryn J-C, Rudolph JL (2005) Why Is the mortality of bullous pemphigoid greater in Europe than in the US? J Invest Dermatol 124(3):xx–xxiGoogle Scholar
  7. 7.
    Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S, Wilkie D, Nicholas R, Chataway J (2017) Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol 16(8):591–600Google Scholar
  8. 8.
    Colbert RL, Allen DM, Eastwood D, Fairley JA (2004) Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 122(5):1091–1095Google Scholar
  9. 9.
    Cortés B, Marazza G, Naldi L, Comescure C, Borradori L, Autoimmune Bullous Disease Swiss Study Group (2011) Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol 165(2):368–374Google Scholar
  10. 10.
    Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI (2007) Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology 46(10):1560–1565Google Scholar
  11. 11.
    Gual A, Mascaró JM Jr, Rojas-Farreras S, Guilabert A, Julià M, Iranzo P (2012) Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre. J Eur Acad Dermatol Venereol 28(4):500–506Google Scholar
  12. 12.
    Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, Vaillant L, D’Incan M, Plantin P, Bedane C, Young P, Bernard P, Bullous Diseases French Study Group (2002) A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 346(5):321–327Google Scholar
  13. 13.
    Joly P, Baricault S, Sparsa A, Bernard P, Bédane C, Duvert-Lehembre S, Courville P, Bravard P, Rémond B, Doffoel-Hantz V, Bénichou J (2012) Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 132(8):1998–2004Google Scholar
  14. 14.
    Joly P, Benichou J, Saiag P, Bernard P, Roujheu JC (2005) Response to: mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 124(3):664–665Google Scholar
  15. 15.
    Jung M, Kippes W, Messer G, Zillikens D, Rzany B (1999) Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. J Am Acad Dermatol 41(2 Pt 1):266–268Google Scholar
  16. 16.
    Kalinska-Bienias A, Lukowska-Smorawska K, Jagielski P, Kowalewski C, Rozniak K (2017) Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland. Arch Dermatol Res 309(9):709–719Google Scholar
  17. 17.
    Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D’Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hmadani M (2017) Recipient immune modulation with atorvastatin for acute graft-versus-host disease prophylaxis after allogeneic transplantation. Biol Blood Marrow Transpl 23(8):1295–1302Google Scholar
  18. 18.
    Kridin K, Bergman R (2018) Ethnic variations in the epidemiology of bullous pemphigoid in Israel. Int J Dermatol 57(1):34–39Google Scholar
  19. 19.
    Lee JH, Kim S-C (2014) Mortality of patients with bullous pemphigoid in Korea. J Am Acad Dermatol 71(4):676–683Google Scholar
  20. 20.
    Li J, Zuo YG, Zheng HY (2013) Mortality of bullous pemphigoid in China. JAMA Dermatol 149(1):106–108Google Scholar
  21. 21.
    Liu YD, Wang YH, Ye YC, Zhao WL, Li L (2017) Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis. Arch Dermatol Res 309(5):335–347Google Scholar
  22. 22.
    Mowla K, Rajai E, Ghorbani A, Dargahi-Malamir M, Bahadoram M, Mohammadi S (2016) Effect of atorvastatin on the disease activity and severity of rheumatoid arthritis: double-blind randomized controlled trial. J Clin Diagn Res 10(5):OC32–OC36Google Scholar
  23. 23.
    Parker SR, Dyson S, Brisman S, Pennie M, Swerlick RA, Khan R, Manos S, Korman BD, Xia Z, Korman NJ (2008) Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 59(4):582–588Google Scholar
  24. 24.
    Risser J, Lewis K, Weinstock MA (2009) Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol 145(9):1005–1008Google Scholar
  25. 25.
    Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P (1998) High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 134(4):465–469Google Scholar
  26. 26.
    Rzany B, Partscht K, Jung M, Kippes W, Mecking D, Baima B, Prudio CM, Pawelczyk B, Messmer EM, Schuhmann M, Sinkgraven R et al (2002) Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 138(7):903–908Google Scholar
  27. 27.
    The Central Bureau of Statistics (Israel) (2018) http://www.cbs.gov.il/reader/?MIval=cw_usr_view_SHTML&ID=705. Accessed 24 Jan 2018
  28. 28.
    Vaillant L, Bernard P, Joly P, Prost C, Labeille B, Bedane C, Arbeille B, thomine E, Bertrand P, Lok C, Roujeau JC (1998) Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French bullous study group. Arch Dermatol 134(9):1075–1080Google Scholar
  29. 29.
    Zeiser R (2018) Immune modulatory effects of statins. Immunology 154(1):69–75Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of DermatologyEmek Medical CenterAfulaIsrael
  2. 2.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations